Covidien names nominees to Mallinckrodt board

DUBLIN -- Global healthcare products company Covidien (NYSE:COV) announced nominees to the future board of directors of Mallinckrodt plc, as the specialty pharmaceutical ingredients company prepares to become a separate, independently traded company in mid-2013. It is expected that eight of the nine nominees will be determined to be independent directors, in accordance with the listing standards of the New York Stock Exchange. The service of all directors is expected to become effective upon the distribution of Mallinckrodt ordinary shares to Covidien shareholders.

Mallinckrodt develops, manufactures, markets and distributes both branded and generic specialty pharmaceuticals, diagnostic imaging agents and active pharmaceutical ingredients, which are sold to other pharmaceutical companies for use in the manufacture of generic pharmaceuticals. Mallinckrodt’s products are found in almost every hospital, standalone diagnostic imaging center or pharmacy in the U.S. With sales in 2012 of $2 billion, Mallinckrodt employs more than 5,300 people worldwide.

Covidien named the following nominees to serve on the Mallinckrodt board of directors:

Melvin D. Booth, 67, will be named chairman of the Board. Mr. Booth is currently a director of Catalent Pharma Solutions, PRA International and eResearch Technologies and is a strategic advisor in life sciences to Genstar Capital. His previous public company board experience includes serving as lead director of Millipore, a life science research company, and as a member of the boards of MedImmune and Human Genome Sciences. Mr. Booth was president of MedImmune from 1998 until his retirement in 2003. Prior to joining MedImmune, Mr. Booth served as president of Human Genome Sciences and held a variety of domestic and international positions with Syntex, including president of its U.S. pharmaceuticals business. He has been active in U.S. pharmaceutical industry organizations and is a past chairman of the Pharmaceuticals Manufacturers Association of Canada.

Mark C. Trudeau, 51, joined Covidien in February 2012 as senior vice president and president of the Pharmaceuticals business. Upon separation, Mr. Trudeau will become president, chief executive officer and a director of Mallinckrodt plc. He joined Covidien from Bayer HealthCare LLC USA, the U.S. healthcare business of Bayer AG, where he served as chief executive officer and simultaneously served as president of Bayer HealthCare Pharmaceuticals, the U.S. organization of Bayer’s global Pharmaceuticals business. Prior to joining Bayer, he headed the Immunoscience Division at Bristol-Myers Squibb where he also held multiple senior roles, including president of the Asia/Pacific region, president and general manager of Canada and general manager/managing director in the United Kingdom. Mr. Trudeau also has previously worked at Abbott Laboratories, Eli Lilly & Co. and E.I. DuPont De Nemours, Inc.

David R. Carlucci, 58, was chairman aadidas superstar damen glitzer silber